These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37645622)

  • 1. Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens.
    Tabernero J; Bedard PL; Bang YJ; Vieito M; Ryu MH; Fagniez N; Chadjaa M; Soufflet C; Masson N; Gazzah A
    Cancer Res Commun; 2023 Aug; 3(8):1662-1671. PubMed ID: 37645622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study.
    Gazzah A; Bedard PL; Hierro C; Kang YK; Abdul Razak A; Ryu MH; Demers B; Fagniez N; Henry C; Hospitel M; Soria JC; Tabernero J
    Ann Oncol; 2022 Apr; 33(4):416-425. PubMed ID: 35026412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors.
    Hassan R; Blumenschein GR; Moore KN; Santin AD; Kindler HL; Nemunaitis JJ; Seward SM; Thomas A; Kim SK; Rajagopalan P; Walter AO; Laurent D; Childs BH; Sarapa N; Elbi C; Bendell JC
    J Clin Oncol; 2020 Jun; 38(16):1824-1835. PubMed ID: 32213105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced or metastatic solid tumors.
    Huang Z; Xu Y; Hong W; Gong L; Chen K; Qin J; Xie F; Wang F; Tian X; Meng X; Feng W; Li L; Zhang B; Kang X; Fan Y
    Front Immunol; 2023; 14():1258573. PubMed ID: 37936687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The search for therapeutic targets in lung cancer: Preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 expression and its associated molecular landscape.
    Lefebvre AM; Adam J; Nicolazzi C; Larois C; Attenot F; Falda-Buscaiot F; Dib C; Masson N; Ternès N; Bauchet AL; Demers B; Chadjaa M; Sidhu S; Combeau C; Soria JC; Scoazec JY; Naimi S; Angevin E; Chiron M; Henry C
    Lung Cancer; 2023 Oct; 184():107356. PubMed ID: 37660479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors.
    Sato J; Shimizu T; Koyama T; Iwasa S; Shimomura A; Kondo S; Kitano S; Yonemori K; Fujiwara Y; Tamura K; Suzuki T; Takase T; Nagai R; Yamaguchi K; Semba T; Zhao ZM; Ren M; Yamamoto N
    Clin Cancer Res; 2022 May; 28(9):1783-1791. PubMed ID: 35180771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors.
    Chiorean EG; LoRusso P; Strother RM; Diamond JR; Younger A; Messersmith WA; Adriaens L; Liu L; Kao RJ; DiCioccio AT; Kostic A; Leek R; Harris A; Jimeno A
    Clin Cancer Res; 2015 Jun; 21(12):2695-703. PubMed ID: 25724527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-in-human study of E7130 (a tumor microenvironment-ameliorating microtubule inhibitor) in patients with advanced solid tumors: Primary results of the dose-escalation part.
    Doi T; Matsubara N; Naito Y; Kuboki Y; Harano K; Ono M; Urasaki T; Ohmoto A; Kawanai T; Hisai T; Ikezawa H; Shiba S; Ito K; Semba T; Asano O; Takahashi S
    Cancer; 2023 Aug; 129(15):2348-2359. PubMed ID: 37080942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors.
    Doi T; Shitara K; Kojima T; Yoshino T; Dontabhaktuni A; Rebscher H; Tang S; Cosaert J; Ohtsu A
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1253-62. PubMed ID: 27139036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Toxicity of Every 2 Weeks Docetaxel Regimen in Comparison With Weekly or Every 3 Weeks in Metastatic Prostate Cancer: A Retrospective Analysis.
    Malhotra A; Welch D; Rosenbaum P; Poiesz BJ
    Am J Clin Oncol; 2016 Jun; 39(3):266-70. PubMed ID: 24662265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study.
    Santin AD; Vergote I; González-Martín A; Moore K; Oaknin A; Romero I; Diab S; Copeland LJ; Monk BJ; Coleman RL; Herzog TJ; Siegel J; Kasten L; Schlicker A; Schulz A; Köchert K; Walter AO; Childs BH; Elbi C; Bulat I
    Int J Gynecol Cancer; 2023 Apr; 33(4):562-570. PubMed ID: 36564099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors.
    Ma Y; Xue J; Zhao Y; Zhang Y; Huang Y; Yang Y; Fang W; Guo Y; Li Q; Ge X; Sun J; Zhang B; Zhang Y; Xiao J; Zhang L; Zhao H
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37263673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.
    Kelly KR; Ailawadhi S; Siegel DS; Heffner LT; Somlo G; Jagannath S; Zimmerman TM; Munshi NC; Madan S; Chanan-Khan A; Lonial S; Chandwani S; Minasyan A; Ruehle M; Barmaki-Rad F; Abdolzade-Bavil A; Rharbaoui F; Herrmann-Keiner E; Haeder T; Wartenberg-Demand A; Anderson KC
    Lancet Haematol; 2021 Nov; 8(11):e794-e807. PubMed ID: 34529955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial.
    Liu D; Zhou J; Wang Y; Li M; Jiang H; Liu Y; Yin X; Ge M; Xiang X; Ying J; Huang J; Zhang YQ; Cheng Y; Huang Z; Yuan X; Han W; Yan D; Wang X; Liu P; Wang L; Zhang X; Luo S; Liu T; Shen L
    BMC Med; 2022 Oct; 20(1):408. PubMed ID: 36280870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101).
    Lakhani N; Cosman R; Banerji U; Rasco D; Tomaszewska-Kiecana M; Garralda E; Kornacki D; Li J; Tian C; Bourayou N; Powderly J
    ESMO Open; 2024 Apr; 9(4):102254. PubMed ID: 38387109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas.
    Piha-Paul SA; Geva R; Tan TJ; Lim DW; Hierro C; Doi T; Rahma O; Lesokhin A; Luke JJ; Otero J; Nardi L; Singh A; Xyrafas A; Chen X; Mataraza J; Bedard PL
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34389618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.
    Juric D; Dienstmann R; Cervantes A; Hidalgo M; Messersmith W; Blumenschein GR; Tabernero J; Roda D; Calles A; Jimeno A; Wang X; Bohórquez SS; Leddy C; Littman C; Kapp AV; Shames DS; Penuel E; Amler LC; Pirzkall A; Baselga J
    Clin Cancer Res; 2015 Jun; 21(11):2462-70. PubMed ID: 26034219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
    Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
    Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors.
    Hyman DM; Rizvi N; Natale R; Armstrong DK; Birrer M; Recht L; Dotan E; Makker V; Kaley T; Kuruvilla D; Gribbin M; McDevitt J; Lai DW; Dar M
    Clin Cancer Res; 2018 Jun; 24(12):2749-2757. PubMed ID: 29559563
    [No Abstract]   [Full Text] [Related]  

  • 20. Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate.
    Pouzin C; Gibiansky L; Fagniez N; Chadjaa M; Tod M; Nguyen L
    J Pharmacokinet Pharmacodyn; 2022 Jun; 49(3):381-394. PubMed ID: 35166967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.